Polypeptide and immune modulation

Patent metadata

Field	Value
Publication number	US-9796762-B2
Application number	US-201414249710-A
Country	US
Kind code	B2
Filing date	Apr 10, 2014
Priority date	Apr 10, 2013
Publication date	Oct 24, 2017
Grant date	Oct 24, 2017

Abstract

The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

First claim

The invention claimed is:

1. A method of treating a gastrointestinal inflammatory disorder or an autoimmune disorder, comprising administering to a subject in need thereof a Roseburia flagellin,
wherein said Roseburia flagellin is a FlaA1 polypeptide with a sequence that has at least 95% identity to SEQ ID NO:2 or a fragment thereof, and
wherein said Roseburia flagellin comprises amino acids 79-117 of SEQ ID NO:2 and binds to TLR5.

2. The method according to claim 1 wherein the gastrointestinal inflammatory disorder or autoimmune disorder affects an alimentary canal, or a section thereof, of said subject.

3. The method according to claim 1 wherein the gastrointestinal inflammatory disorder or autoimmune disorder affects a mucosal site of said subject, such as an esophagus, stomach, or intestine.

4. The method according to claim 1 wherein the gastrointestinal inflammatory disorder or autoimmune disorder affects an intestine.

5. The method according to claim 1 wherein the subject is treated for an autoimmune disorder, wherein the autoimmune disorder is neutropenia.

6. The method according to claim 1 wherein said Roseburia flagellin comprises the polypeptide of SEQ ID NO:2 or a fragment thereof.

7. The method according to claim 1 wherein the Roseburia flagellin is a truncated FlaA1 polypeptide, and wherein said truncated FlaA1 polypeptide binds to TLR5 when administered to the subject.

8. The method according to claim 7 wherein the subject is administered the truncated FlaA1 polypeptide, wherein the truncated FlaA1 polypeptide comprises at least 40 amino acids of a polypeptide of SEQ ID NO:2.

9. The method of claim 1 , wherein the subject is treated for a gastrointestinal inflammatory disorder selected from the group consisting of irritable bowel syndrome (IBS), colitis, and inflammatory bowel disorder (IBD).

10. The method of claim 1 , wherein the subject is treated for a gastrointestinal inflammatory disorder, wherein the gastrointestinal inflammatory disorder is Crohn's disease.

11. The method of claim 1 , wherein the subject is treated for an autoimmune disorder selected from the group consisting of ulcerative colitis and pouchitis.

12. The method of claim 1 , wherein said FlaA1 polypeptide has at least 97% identity to the polypeptide of SEQ ID NO:2 or a fragment thereof.

13. The method of claim 1 , wherein said FlaA1 polypeptide has at least 98% identity to the polypeptide of SEQ ID NO:2 or a fragment thereof.

14. The method of claim 1 , wherein said FlaA1 polypeptide has at least 99% identity to the polypeptide of SEQ ID NO:2 or a fragment thereof.

15. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 50 amino acids of a polypeptide of SEQ ID NO:2.

16. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 75 amino acids of a polypeptide of SEQ ID NO:2.

17. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 100 amino acids of a polypeptide of SEQ ID NO:2.

18. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 125 amino acids of a polypeptide of SEQ ID NO:2.

19. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 150 amino acids of a polypeptide of SEQ ID NO:2.

20. The method according to claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 175 amino acids of a polypeptide of SEQ ID NO:2.

21. The method of claim 1 , wherein the subject is treated for a gastrointestinal inflammatory disorder.

22. The method of claim 1 , wherein the subject is treated for an autoimmune disorder.

Assignees

• 4D Pharma Res Ltd

Inventors

• Kelly Denise
• Patterson Angela
• Monnais Edouard
• Mulder Imke

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title